The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
A study of monoclonal antibody‐producing CHO cell lines: What makes a stable high producer?
Open accessAbstract
Generating stable, high‐producing cell lines for recombinant protein production requires an understanding of the potential limitations in the cellular machinery for protein expression. In order to increase our understanding of what makes a stable high producer, we have generated a panel of 17 recombinant monoclonal antibody expressing Chinese hamster ovary subclones (CHO‐mAb) with specific productivities ranging between 3 and 75 pg cell−1 day−1 using the dihydrofolate reductase (dhfr) expression system and compared the molecular features of these high‐ and low‐producer clones. The relative heavy chain (HC) and light chain (LC) transgene copy numbers and mRNA levels were determined using real‐time quantitative PCR (RT qPCR). We observed that not only higher transgene copy numbers and mRNA levels of both HC and LC were characteristic for the high‐producer clones as compared to the low‐producer clones but also a more favorable HC to LC transgene copy numbers ratio. By studying the long‐term stability of the CHO‐mAb subclones in the absence of methotrexate (MTX) selective pressure over 36 passages we observed a 35–92% decrease in volumetric productivity, primarily caused by a significant decrease in HC and LC mRNA levels with little change in the transgene copy numbers. Using Southern blot hybridization we analyzed the HC and LC transgene integration patterns in the host chromosome and their changes in course of gene amplification and long‐term culturing. We observed that MTX‐induced gene amplification caused chromosomal rearrangements resulting in clonal variability in regards to growth, productivity, and stability. No further obvious DNA rearrangements occurred during long‐term culturing in the absence of MTX, indicating that other mechanisms were responsible for the decreased transcription efficiency. Our results implicate that the amplified transgene sequences were arranged in tandem repeats potentially triggering repeat‐induced gene silencing. We hypothesize that the decline in transgene mRNA levels upon long‐term culturing without MTX was mainly caused by transgene silencing consequently leading to a loss in mAb productivity. The exact molecular mechanisms causing production instability are not yet fully understood. The herein described extensive characterization studies could help understand the limitations to high‐level, stable recombinant protein production and find ways to improving and accelerating the process for high‐producer cell line generation and selection. Biotechnol. Bioeng. 2009;102: 1182–1196. © 2008 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Southern, P. J., & Berg, P. R. (1982) · PubMed · Cited by 2,740
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Alt, F. W., Kellems, R. E., Bertino, J. R., & Schimke, R. T. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34875-5 · Cited by 941
Epigenetic Codes for Heterochromatin Formation and Silencing
Richards, E. J., & Elgin, S. C. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00644-x · Cited by 871
Genetic and physical linkage of exogenous sequences in transformed cells
Perucho, M., Hanahan, D., & Wigler, M. (1980) · Cell · doi:10.1016/0092-8674(80)90178-6 · Cited by 455
Pikaart, M. J., Recillas-Targa, F., & Felsenfeld, G. (1998) · Genes & Development · doi:10.1101/gad.12.18.2852 · Cited by 397
Position effects on eukaryotic gene expression
Wilson, C., Bellen, H. J., & Gehring, W. J. (1990) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.06.110190.003335 · Cited by 379
Subramani, S., Mulligan, R., & Berg, P. (1981) · Molecular and Cellular Biology · doi:10.1128/mcb.1.9.854 · Cited by 299
Kaufman, R. J., Wasley, L. C., Spiliotes, A. J., Gossels, S. D., Latt, S. A., Larsen, G. R., & Kay, R. M. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.7.1750 · Cited by 297
Cited by
Advances in Mammalian cell line development technologies for recombinant protein production
Lai, T., Yang, Y., & Ng, S. (2013) · Pharmaceuticals · doi:10.3390/ph6050579 · Cited by 322
Self-citationmRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo
Rybakova, Y., Kowalski, P. S., Huang, Y., Gonzalez, J. T., Heartlein, M. W., DeRosa, F., Delcassian, D., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.012 · Cited by 218
Guidelines to cell engineering for monoclonal antibody production
Rita Costa, A., Elisa Rodrigues, M., Henriques, M., Azeredo, J., & Oliveira, R. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.10.002 · Cited by 178
Osterlehner, A., Simmeth, S., & Göpfert, U. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23216 · Cited by 131
Erasmus, J. H., Archer, J., Fuerte-Stone, J., Khandhar, A. P., Voigt, E., Granger, B., Bombardi, R. G., Govero, J., Tan, Q., Durnell, L. A., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.011 · Cited by 118
Stolfa, G., Smonskey, M. T., Boniface, R., Hachmann, A., Gulde, P., Joshi, A. D., Pierce, A. P., Jacobia, S. J., & Campbell, A. (2018) · Biotechnology Journal · doi:10.1002/biot.201700227 · Cited by 97
Chong, W. P. K., Reddy, S. G., Yusufi, F. N. K., Lee, D.-Y., Wong, N. S. C., Heng, C. K., Yap, M. G. S., & Ho, Y. S. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.03.018 · Cited by 97
Self-citationGhorbaniaghdam, A., Chen, J., Henry, O., & Jolicoeur, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090832 · Cited by 71
High-level transgene expression by homologous recombination-mediated gene transfer
Grandjean, M., Girod, P.-A., Calabrese, D., Kostyrko, K., Wicht, M., Yerly, F., Mazza, C., Beckmann, J. S., Martinet, D., & Mermod, N. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr436 · Cited by 53
del Val, I. J., Polizzi, K. M., & Kontoravdi, C. (2016) · Scientific Reports · doi:10.1038/srep28547 · Cited by 41
Metabolomic profiling of CHO fed-batch growth phases at 10, 100 and 1, 000 L
Vodopivec, M., Lah, L., Narat, M., & Curk, T. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27087 · Cited by 37
Harraghy, N., Regamey, A., Girod, P.-A., & Mermod, N. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.04.004 · Cited by 37
Fan, L., Frye, C. C., & Racher, A. J. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.56 · Cited by 35
Harraghy, N., Calabrese, D., Fisch, I., Girod, P., LeFourn, V., Regamey, A., & Mermod, N. (2015) · Biotechnology Journal · doi:10.1002/biot.201400649 · Cited by 32
Using matrix attachment regions to improve recombinant protein production
Harraghy, N., Buceta, M., Regamey, A., Girod, P.-A., & Mermod, N. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-352-3_7 · Cited by 30
Chitwood, D. G., Wang, Q., Klaubert, S. R., Green, K., Wu, C. H., Harcum, S. W., & Saski, C. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-27962-0 · Cited by 12
Evaluation of the OSCAR™ system for the production of monoclonal antibodies by CHO-K1 cells
Costa, A. R., Rodrigues, M. E., Henriques, M., Melton, D., Cunnah, P., Oliveira, R., & Azeredo, J. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.028 · Cited by 12
Metadata
- Authors
- Chusainow, J., Yang, Y. S., Yeo, J. H. M., Toh, P. C., Asvadi, P., Wong, N. S. C., & Yap, M. G. S.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2008-10-31
- Volume
- 102
- Issue
- 4
- Pages
- 1182-1196
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2121074166
- Cited by
- 313
- References
- 45
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
